Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 17/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.58 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.58 |
| ▸ | ITGAM | P11215 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12518900 | 0.93 | MIF (0.72) | MIFHDAC6ITGB3ITGA2BITGB2 | |
| SCHEMBL12556242 | 0.88 | ITGB3 (0.74) | MIFHDAC6ITGB3ITGA2BITGB2 | |
| SCHEMBL12556240 | 0.85 | MIF (0.74) | MIFHDAC6ITGB3ITGA2BITGB2 | |
| SCHEMBL12518910 | 0.85 | MIF (0.74) | MIFHDAC6ITGB3ITGA2BITGB2 | |
| SCHEMBL12556116 | 0.83 | MIF (0.71) | MIFHDAC6ITGB3ITGA2BITGB2 | |
| SCHEMBL12556120 | 0.83 | MIF (0.65) | MIFHDAC6ITGB3ITGA2B | |
| SCHEMBL12518895 | 0.82 | MIF (0.74) | MIFHDAC6ITGB3ITGA2BITGB2 | |
| SCHEMBL14189254 | 0.82 | MIF (0.65) | MIFHDAC6ITGB3ITGA2BITGB2 | |
| SCHEMBL14189256 | 0.81 | MIF (0.63) | MIFHDAC6ITGB3ITGA2B | |
| SCHEMBL15143914 | 0.80 | MIF (0.78) | MIFHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| US-20130225586-A1 | COMPOUNDS, COMPOSITIONS, PROCESSES OF MAKING, AND METHODS OF USE RELATED TO INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR | CPSI STOCKHOLDER TRUST (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225586-A1 | COMPOUNDS, COMPOSITIONS, PROCESSES OF MAKING, AND METHODS OF USE RELATED TO INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR | CPSI STOCKHOLDER TRUST (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130196996-A1 | USE OF ISOXAZOLINE COMPOUNDS AND COMPOSITIONS IN BLADDER CANCER | CPSI STOCKHOLDER TRUST (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196996-A1 | USE OF ISOXAZOLINE COMPOUNDS AND COMPOSITIONS IN BLADDER CANCER | CPSI STOCKHOLDER TRUST (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130172553-A1 | CHIRAL SYNTHESIS OF ISOXAZOLINES, ISOXAZOLINE COMPOUNDS, AND USES THEREOF | CPSI STOCKHOLDER TRUST (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172553-A1 | CHIRAL SYNTHESIS OF ISOXAZOLINES, ISOXAZOLINE COMPOUNDS, AND USES THEREOF | CPSI STOCKHOLDER TRUST (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2011066482-A2 | CHIRAL SYNTHESIS OF ISOXAZOLINES, ISOXAZOLINE COMPOUNDS, AND USES THEREOF | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
| US-20080113997-A1 | COMPOUNDS, COMPOSITIONS, PROCESSES OF MAKING, AND METHODS OF USE RELATED TO INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113997-A1 | COMPOUNDS, COMPOSITIONS, PROCESSES OF MAKING, AND METHODS OF USE RELATED TO INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225586-A1 | COMPOUNDS, COMPOSITIONS, PROCESSES OF MAKING, AND METHODS OF USE RELATED TO INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MSR1, MRGPRX2 | MIF 1/4885HDAC6 1161/4885ITGB3 618/4885 |
| US-20130172553-A1 | CHIRAL SYNTHESIS OF ISOXAZOLINES, ISOXAZOLINE COMPOUNDS, AND USES THEREOF | CYP3A7, CYP2A7, UGT1A7 | MIF 3650/4885HDAC6 1581/4885ITGB3 2023/4885 |
| US-20130196996-A1 | USE OF ISOXAZOLINE COMPOUNDS AND COMPOSITIONS IN BLADDER CANCER | INMT, BTF3, BPGM | MIF 1034/4885HDAC6 606/4885ITGB3 805/4885 |
| US-20080113997-A1 | COMPOUNDS, COMPOSITIONS, PROCESSES OF MAKING, AND METHODS OF USE RELATED TO INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MSR1, MRGPRX2 | MIF 1/4885HDAC6 1161/4885ITGB3 618/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | MIF 1/4885HDAC6 2014/4885ITGB3 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.